Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 6, 1999, Pages 829-835

  Burke, Sandra E ^a   Lubbers, Nathan L ^a   Chen, Yung Wu ^a   Hsieh, Gin C ^a   Mollison, Karl W ^a   Luly, Jay R ^a   Wegner, Craig D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Angioplasty; Minipig; Neointima; Rapamycin; Restenosis

Indexed keywords

METHYLCELLULOSE; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE; CAROTID ARTERY OBSTRUCTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LYMPHOCYTE PROLIFERATION; MALE; MORPHOMETRICS; NONHUMAN; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RESTENOSIS; SWINE;

ANGIOPLASTY, BALLOON; ANIMALS; ANTI-BACTERIAL AGENTS; BLOOD PRESSURE; CAROTID ARTERIES; CAROTID ARTERY INJURIES; CAROTID STENOSIS; CELL DIVISION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HEART RATE; LYMPHOCYTES; MALE; SIROLIMUS; SWINE; SWINE, MINIATURE; TUNICA INTIMA;

EID: 0033044882     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199906000-00001     Document Type: Article

References (31)

1. King SB III. Angioplasty from bench to bedside to bench. Circulation 1996;93:1621-9.
2. Jackson CL. Animal models of restenosis. Trends Cardiovasc Med 1994;4:122-30.
3. Davies MG, Hagen P-O. Pathobiology of intimai hyperplasia. Br J Surg 1994;81:1254-69.
4. Herman JR, Hermans WRM, Vos J, Serruys PW. Pharmacological approaches to the prevention of restenosis following angioplasty. Drugs 1993;46:18-52.
5. Morris RE, Meiser BM, Wu J, Shorthouse R, Wang R. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 1991;23:521-4.
6. Collier D St J, Calne R, Thiru S, et al. Rapamycin in experimental renal allografts in dogs and pigs. Transplant Proc 1990;22:1674-5.
7. Granger DK, Cromwell JW, Chen SC, et al. Prolongation of renal allograft survival in a large animal model by oral rapamycin monotherapy. Transplantation 1995;59:183-6.
8. Almond PS, Moss A, Nakhieh R, et al. Rapamycin in a porcine renal transplant model. Transplant Proc 1993;25:716.
9. Collier DStJ, Calne R, Pollard SG, Friend PJ, Thiru S. Rapamycin in experimental renal allografts in primates. Transplant Proc 1991; 23:2246-7.
10. Kahan BD, Murgiz MG, Slaton J, Napoli K. Potential applications of therapeutic drug monitoring of sirolimus immunosuppression in clinical renal transplantation. Ther Drug Monit 1995;17:672-5.
11. 1/S-phase growth arrest in T lymphocytes. J Biol Chem 1993;268:3734-8.
12. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990;144: 251-8.
13. Akselband Y, Harding MW, Nelson PA. Rapamycin inhibits spontaneous and fibroblast growth factor β-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 1991;23:2833-6.
14. Francavilla A, Starzl TE, Carr B, et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. Transplant Proc 1991;23:2817-20.
15. Gregory CR, Huie P, Billingham ME, Morris RE. Rapamycin inhibits arterial intimai thickening caused by both alloimmune and mechanical injury. Transplantation 1993;55:1409-18.
16. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-7.
17. Gregory CR, Huang X, Pratt RE, et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimai thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995;59:655-61.
18. Goggins WC, Fisher RA, Cohen DS, Tawes JW, Grimes MM. Effect of single-dose rapamycin-based immunosuppression on the development of cardiac allograft vasculopathy. J Heart Lung Transplant 1996;15:790-5.
19. Schwanz RS, Murphy JG, Edwards WD, Camrud AR, Wliestra RE, Holmes DR. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990; 82:2190-200.
20. Schwartz RS, Chu A, Edwards WD, et al. A proliferation analysis of arterial neointimal hyperplasia: lessons for antiproliferative restenosis therapies. Int J Cardiol 1996;53:71-80.
21. Gallo R, Padurean A, Chesebro JH, et al. Rapamycin (Sirolimus) reduces luminal narrowing after balloon angioplasty in porcine coronary arteries [Abstract]. J Am Coll Cardiol 1996;27:198A.
22. Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105-12.
23. Schwartz RS, Koval TM, Edwards WD, et al. Effect of external beam irradiation on neointimal hyperplasia after experimental coronary artery injury. J Am Coll Cardiol 1992;19:1106-13.
24. Lam JYT, Lacoste L, Bourassa MG. Cilazapril and early atherosclerotic changes after balloon injury of porcine carotid arteries. Circulation 1992;85:1542-7.
25. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Transplantation 1995;59:390-5.
26. Morris RE, Cao W, Huang X, et al. Rapamycin (Sirolimus) inhibits vascular smooth muscle synthesis in vitro and suppresses narrowing in arterial allografts and in balloon-injured carotid arteries: evidence that rapamycin antagonizes growth factor action on immune and non-immune cells. Transplant Proc 1995;27:430-1.
27. 1 phase of the cycle. J Cell Physiol 1993;154:7-15.
28. Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J. Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 1995;17:666-71.
29. Slaton JW, Kahan BD. Case report: sirolimus rescue therapy for refractory renal allograft rejection. Transplantation 1996;61: 977-9.
30. Kahan BD, Chang JY, Sehgal S. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin. Transplantation 1991;52:185-91.
31. Leach CM, Thorburn GD. A comparative study of collagen induced thromboxane release from platelets of different species: implications for human atherosclerosis models. Prostaglandins 1982; 24:47-59.